Short communication: Use of serum bilirubin levels as surrogate marker of early virological response to atazanavir-based antiretroviral therapy

AIDS Research and Human Retroviruses

Volumn 27, Issue 10, 2011, Pages 1043-1045

  Morello, Judit ^a   Álvarez, Elena ^a   Cuenca, Lorena ^a   Vispo, Eugenia ^a   González Lahoz, Juan ^a   Soriano, Vincent ^a   Rodríguez Nóvoa, Sonia ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; BILIRUBIN; GLUCURONOSYLTRANSFERASE 1A1; TENOFOVIR; VIRUS RNA;

BILIRUBIN BLOOD LEVEL; CD4+ T LYMPHOCYTE; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; NONHUMAN; PREDICTIVE VALUE; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; VIROTHERAPY; VIRUS LOAD;

ADULT; ALLELES; BILIRUBIN; BIOLOGICAL MARKERS; CD4 LYMPHOCYTE COUNT; COINFECTION; FEMALE; FOLLOW-UP STUDIES; GLUCURONOSYLTRANSFERASE; HEPATITIS C; HIV; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; OLIGOPEPTIDES; PYRIDINES; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RNA, VIRAL; ROC CURVE; VIRAL LOAD;

EID: 80053639842     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2011.0019     Document Type: Review

References (9)

1. Rivas P, Morello J, Garrido C, Rodriguez-Novoa S, and Soriano V: Role of atazanavir in the treatment of HIV infection. Ther Clin Risk Manag 2009;5:99-116.
2. Zhang D, Chando TJ, Everett DW, Patten CJ, Dehal SS, and Humphreys WG: In vitro inhibition of UDP glucuronosyl-transferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab Dispos 2005;33: 1729-1739. (Pubitemid 41539973)
3. Rodriguez-Novoa S, Martin-Carbonero L, Barreiro P, et al.: Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia. AIDS 2007;21:41-46. (Pubitemid 44912535)
4. Rodriguez Novoa S, Barreiro P, Rendon A, et al.: Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C/T polymorphism at the multidrug resistance gene 1. Clin Infect Dis 2006;42:291-295. (Pubitemid 43054206)
5. La Porte CJL, Back DJ, Blaschke T, Boucher CAB, Fletcher CV, and Flexner JG: Updated guideline to perform therapeutic drug monitoring for antiretroviral agents. Rev Antiviral Ther 2008;3:3-14.
6. Division of AIDS Table for Grading the severity of adult and pediatric adverse events Version 1.0, December 2004; clarification August 2009. http://rsc.tech-res.com/safetyandpharmacovigilance/.
7. Hung CH, Lee CM, Lu SN, et al.: Anemia associated with antiviral therapy in chronic hepatitis C: Incidence, risk factors, and impact on treatment response. Liver Int 2006;26: 1079-1086.
8. Lindahl K, Stahle L, Bruchfeld A, and Schvarcz R: High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Hepatology 2005;41:275-279. (Pubitemid 40165370)
9. Petersen K, Riddle MS, Jones LE, et al.: Use of bilirubin as a marker of adherence to atazanavir-based antiretroviral therapy. AIDS 2005;19:1700-1702. (Pubitemid 41502687)